Recombinant IL-2 Shows Potential in Atopic Dermatitis

"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.

Related Keywords

Washington ,United States ,Netherlands ,Amsterdam ,Noord Holland ,Berlin ,Germany ,Reis Matos ,Jonathan Silverberg ,Eli Lilly ,Health Science ,Amsterdam University Medical Centers ,George Washington University School Of Medicine ,European Academy Of Dermatology ,Nektar Therapeutics ,European Academy ,Eczema Area ,Severity Index ,Body Surface Area ,George Washington University School ,Medscape Medical News ,Peace Corps ,Validated Investigator Global Assessment ,Atopic Dermatitis ,Itch Numeric Rating Scale ,Dermatology Life Quality Index ,Patient Oriented Eczema Measure ,Dermatitis ,Biologic Therapy ,Interleukin 2 ,Sol 2 ,Adverse Effects ,Side Effects ,Clinical Research ,Clinical Trials ,Linical Studies ,Eczema ,Interleukins ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Severity Indices ,